BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 33483421)

  • 1. Large remodeling of the Myc-induced cell surface proteome in B cells and prostate cells creates new opportunities for immunotherapy.
    Chen W; Mou KY; Solomon P; Aggarwal R; Leung KK; Wells JA
    Proc Natl Acad Sci U S A; 2021 Jan; 118(4):. PubMed ID: 33483421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Broad and thematic remodeling of the surfaceome and glycoproteome on isogenic cells transformed with driving proliferative oncogenes.
    Leung KK; Wilson GM; Kirkemo LL; Riley NM; Coon JJ; Wells JA
    Proc Natl Acad Sci U S A; 2020 Apr; 117(14):7764-7775. PubMed ID: 32205440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High susceptibility of metastatic cells derived from human prostate and colon cancer cells to TRAIL and sensitization of TRAIL-insensitive primary cells to TRAIL by 4,5-dimethoxy-2-nitrobenzaldehyde.
    Kim HB; Kim MJ; Kim DY; Lee JW; Bae JH; Kim DW; Kang CD; Kim SH
    Mol Cancer; 2011 Apr; 10():46. PubMed ID: 21513580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitivity of malignant peripheral nerve sheath tumor cells to TRAIL is augmented by loss of NF1 through modulation of MYC/MAD and is potentiated by curcumin through induction of ROS.
    Reuss DE; Mucha J; Hagenlocher C; Ehemann V; Kluwe L; Mautner V; von Deimling A
    PLoS One; 2013; 8(2):e57152. PubMed ID: 23437333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Affinity Maturation of B7-H6 Translates into Enhanced NK Cell-Mediated Tumor Cell Lysis and Improved Proinflammatory Cytokine Release of Bispecific Immunoligands via NKp30 Engagement.
    Pekar L; Klausz K; Busch M; Valldorf B; Kolmar H; Wesch D; Oberg HH; Krohn S; Boje AS; Gehlert CL; Toleikis L; Krah S; Gupta T; Rabinovich B; Zielonka S; Peipp M
    J Immunol; 2021 Jan; 206(1):225-236. PubMed ID: 33268483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bcl-2 is a better therapeutic target than c-Myc, but attacking both could be a more effective treatment strategy for B-cell lymphoma with concurrent Bcl-2 and c-Myc overexpression.
    Sasaki N; Kuroda J; Nagoshi H; Yamamoto M; Kobayashi S; Tsutsumi Y; Kobayashi T; Shimura Y; Matsumoto Y; Taki T; Nishida K; Horiike S; Akao Y; Taniwaki M
    Exp Hematol; 2011 Aug; 39(8):817-28.e1. PubMed ID: 21640157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upregulation of Death Receptor 5 and Production of Reactive Oxygen Species Mediate Sensitization of PC-3 Prostate Cancer Cells to TRAIL Induced Apoptosis by Vitisin A.
    Shin D; Kwon HY; Sohn EJ; Nam MS; Kim JH; Lee JC; Ryu SY; Park B; Kim SH
    Cell Physiol Biochem; 2015; 36(3):1151-62. PubMed ID: 26111475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preferential Expression of B7-H6 in Glioma Stem-Like Cells Enhances Tumor Cell Proliferation via the c-Myc/RNMT Axis.
    Chen H; Guo Y; Sun J; Dong J; Bao Q; Zhang X; Fu F
    J Immunol Res; 2020; 2020():2328675. PubMed ID: 32322592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pim1 promotes human prostate cancer cell tumorigenicity and c-MYC transcriptional activity.
    Kim J; Roh M; Abdulkadir SA
    BMC Cancer; 2010 Jun; 10():248. PubMed ID: 20515470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MYC Protein-positive Diffuse Large B-Cell Lymphoma Features an Activated B-Cell Receptor Signal Pathway.
    Wang WG; Jiang XN; Liu ZB; Zhou XY; Li XQ
    Am J Surg Pathol; 2017 Apr; 41(4):541-549. PubMed ID: 28291124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A regulatory loop among CD276, miR-29c-3p, and Myc exists in cancer cells against natural killer cell cytotoxicity.
    Lee CC; Ho KH; Huang TW; Shih CM; Hsu SY; Liu AJ; Chen KC
    Life Sci; 2021 Jul; 277():119438. PubMed ID: 33798549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity.
    Xu Y; Xiao Y; Luo C; Liu Q; Wei A; Yang Y; Zhao L; Wang Y
    Int Immunopharmacol; 2020 Jul; 84():106584. PubMed ID: 32422527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Molecular mechanism of cisplatin to enhance the ability of TRAIL in reversing multidrug resistance in gastric cancer cells].
    Zhu X; Zhang K; Wang Q; Chen S; Gou Y; Cui Y; Li Q
    Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):404-11. PubMed ID: 26463141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B7-H3 as a promising target for cytotoxicity T cell in human cancer therapy.
    Ma J; Ma P; Zhao C; Xue X; Han H; Liu C; Tao H; Xiu W; Cai J; Zhang M
    Oncotarget; 2016 May; 7(20):29480-91. PubMed ID: 27121051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The proto-oncogene Myc drives expression of the NK cell-activating NKp30 ligand B7-H6 in tumor cells.
    Textor S; Bossler F; Henrich KO; Gartlgruber M; Pollmann J; Fiegler N; Arnold A; Westermann F; Waldburger N; Breuhahn K; Golfier S; Witzens-Harig M; Cerwenka A
    Oncoimmunology; 2016 Jul; 5(7):e1116674. PubMed ID: 27622013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. c-Myc plays a role in cellular susceptibility to death receptor-mediated and chemotherapy-induced apoptosis in human monocytic leukemia U937 cells.
    Dong J; Naito M; Tsuruo T
    Oncogene; 1997 Aug; 15(6):639-47. PubMed ID: 9264404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A TRAIL receptor-dependent synthetic lethal relationship between MYC activation and GSK3beta/FBW7 loss of function.
    Rottmann S; Wang Y; Nasoff M; Deveraux QL; Quon KC
    Proc Natl Acad Sci U S A; 2005 Oct; 102(42):15195-200. PubMed ID: 16210249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypoxia-inducible factor-2alpha regulates the expression of TRAIL receptor DR5 in renal cancer cells.
    Mahajan S; Dammai V; Hsu T; Kraft AS
    Carcinogenesis; 2008 Sep; 29(9):1734-41. PubMed ID: 18544564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD19 is a major B cell receptor-independent activator of MYC-driven B-lymphomagenesis.
    Chung EY; Psathas JN; Yu D; Li Y; Weiss MJ; Thomas-Tikhonenko A
    J Clin Invest; 2012 Jun; 122(6):2257-66. PubMed ID: 22546857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen receptor (AR) suppresses normal human prostate epithelial cell proliferation via AR/β-catenin/TCF-4 complex inhibition of c-MYC transcription.
    Antony L; van der Schoor F; Dalrymple SL; Isaacs JT
    Prostate; 2014 Aug; 74(11):1118-31. PubMed ID: 24913829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.